Market Overview

Gilead Sciences Falls Ever-So-Slightly After Q4 Earnings Beat

Related GILD
Early Global News: Ebola In Liberia, Boeing To Roll Out 737 MAX Next Month, Google Testing SMS Alerts
Gilead's Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Strong Drug Development Benefits Cambrex (Investor's Business Daily)

Gilead Sciences (NASDAQ: GILD) is down less than one percent in after hours trading after the company announced its fourth quarter results.

The company reported a Q4 EPS of $0.55 versus the Street estimate of $0.50.

Earnings per share were up 10 percent from the year-ago period.

Revenue arrived at $3.12 billion versus the Street estimate of $2.85 billion. Sales were up 20 percent year-over-year.

Gilead also announced that product sales increased 21 percent to $3.04 billion for the fourth quarter of 2013. This is notably higher than the $2.51 billion that Gilead reported during the fourth quarter of 2012.

Full year product sales rose to $10.8 billion (up from $9.4 billion in 2012). Sales of Stribild, Complera, Eviplera and Sovaldi were attributed to the company's continued success.

Antiviral product sales also increased, rising 22 percent to $2.64 billion during the fourth quarter. For all of 2013, antiviral product sales reached $9.34 billion -- up from $8.14 billion during the previous year.

At market close yesterday (Monday, February 3, 2014), Gilead was up more than four percent year-to-date.

The stock has performed well over the past year, rising more than 99 percent since February 4, 2013.

Disclosure: At the time of this writing, Louis Bedigian had no position in the equities mentioned in this report.

Posted-In: Complera Eviplera Gilead Sciences Sovaldi StribildEarnings News


Related Articles (GILD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters